High throughput proteomic strategies for identifying tumour-associated antigens

Abstract Tumours elicit an immune response in the host organism and this area has been studied for decades. Initially, tumour-associated antigens were studied by examining a few proteins at a time using techniques such as 1-D SDS–PAGE and sandwich ELISAs. Now, however, with the development of high-t...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2007-04, Vol.249 (1), p.110-119
Main Authors: Gunawardana, C. Geeth, Diamandis, Eleftherios P
Format: Article
Language:English
Subjects:
Antigens, Neoplasm - genetics
Antigens, Neoplasm - metabolism
Autoantibodies - genetics
Autoantibodies - metabolism
Biomarkers
Cancer
Cloning
Experiments
Gene Library
Hematology, Oncology and Palliative Medicine
Humans
Libraries
Melanoma
Neoplasm Proteins - genetics
Neoplasm Proteins - metabolism
Neoplasms - genetics
Neoplasms - immunology
Neoplasms - metabolism
Protein Array Analysis
Protein microarray
Proteins
Proteomics
SEREX
SERPA
Tumour-associated antigens
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Tumours elicit an immune response in the host organism and this area has been studied for decades. Initially, tumour-associated antigens were studied by examining a few proteins at a time using techniques such as 1-D SDS–PAGE and sandwich ELISAs. Now, however, with the development of high-throughput strategies, multiple potential antigens in a single experiment could be uncovered. The prevailing view is that these antigens can be used as biosensors for cancers. In addition, some of these antigens may indeed be used as targets for immunotherapy. SEREX, SERPA, and protein microarray technology have been the three dominant strategies employed to identify tumour-associated antigens. In this mini-review, we aim to describe these three techniques and provide their advantages and disadvantages. In addition, we aim to address some of the challenges of cancer immunomics.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2007.01.002